Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15001003 | 1.00 | RAB9A (0.47) | RAB9AMAPTNOS3NOS2KDM4E | |
| SCHEMBL24115295 | 0.80 | RAB9A (0.43) | RAB9AMAPTKDM4ECCR1CCR5 | |
| SCHEMBL15984552 | 0.80 | KDM4E (0.44) | RAB9AMAPTKDM4ECCR1CCR5 | |
| SCHEMBL23807001 | 0.78 | RAB9A (0.52) | RAB9AMAPTNOS3NOS2KDM4E | |
| SCHEMBL47334 | 0.74 | HCAR3 (0.44) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL16316772 | 0.73 | GAA (0.52) | RAB9AMAPTKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL16316773 | 0.73 | RAB9A (0.46) | RAB9AMAPTKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL1108676 | 0.73 | RAB9A (0.46) | RAB9AMAPTKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL1108655 | 0.73 | GAA (0.52) | RAB9AMAPTKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL8539297 | 0.73 | MAPT (0.60) | RAB9AMAPTNPC1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151772-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF ANGPTL3, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SIRIUS THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024073363-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SIRIUS THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024035898-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SIRIUS THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2024035899-A2 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | SIRIUS THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2020081744-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | TOLLNINE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2018035380-A1 | POLYNUCLEOTIDE CONSTRUCTS | SOLSTICE BIOLOGICS, LTD. (IE) | 2018-02-22 | — | — | WO | disclosed |
| US-8916708-B2 | Urea derivatives and their therapeutic use in the treatment of, inter alia, diseases of the respiratory tract | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-23 | — | — | US | disclosed |
| US-8557797-B2 | Triazolopyridine derivatives and their therapeutic use | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-10-15 | — | — | US | disclosed |
| US-20130143914-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-06 | — | — | US | disclosed |
| US-20120088763-A1 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143914-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | ARG2, MAPK1, URB2 | RAB9A 1255/4885MAPT 3232/4885NOS3 115/4885 |
| US-20120088763-A1 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | CNKSR1, MOK, MAPK1 | RAB9A 1762/4885MAPT 4493/4885NOS3 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.